Navigation Links
Alimera Sciences Reports Third Quarter 2013 Financial Results
Date:11/11/2013

ATLANTA, Nov. 11, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the third quarter ended September 30, 2013.

Total revenue from ILUVIEN, comprised of sales in Germany and the United Kingdom in the third quarter of 2013, increased 323% to $758,000, compared to second quarter 2013 revenue of $179,000.

In addition to its current activity in Germany and the United Kingdom, the Company anticipates a commercial launch of ILUVIEN in France in 2014. ILUVIEN is also approved in Austria, Portugal, and Spain, and pending approval in Italy. In the third quarter, Alimera submitted an application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, as the Reference Member State, for 10 additional European Union (EU) country approvals through the Mutual Recognition Procedure, which could provide Alimera a pipeline for geographic expansion in the future. Alimera believes Europe offers the possibility of significant growth and estimates the market opportunity in Europe to be at least as large as that in the United States.  

"During the third quarter, our commercial focus on Europe continued to grow as we increased revenue over 300% and expanded the number of physicians implanting ILUVIEN in their patients in Germany and the United Kingdom," said Dan Myers, Alimera's president and chief executive officer.

FDA UpdateOn October 17, 2013, Alimera received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA stated in the CRL that the NDA could not be approved in its present form, citing clinical and statistical deficiencies and indicated th
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
2. Alimera Sciences Reports Second Quarter 2013 Financial Results
3. Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results
4. Alimera Sciences Reports First Quarter 2013 Financial Results
5. Alimera Sciences Secures $20 Million Debt Facility
6. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
7. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
8. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
9. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
10. Alimera Sciences Names European Management Team
11. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SUNNYVALE, Calif., July 31, 2014 Pharmacyclics, Inc. (the ... and recent developments for the quarter ended June 30, 2014. ... Ended June 30, 2014 Revenue Total revenue for the ... $54.7 million for the quarter ended June 30, 2013 primarily ... $109.5 million. Total revenue for the six ...
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
(Date:7/31/2014)... , July 31, 2014 Touro University California,s ... been selected as the recipient of a $150,000 grant ... allow the University to increase research and classroom space ... state-of-the-art technology for the study of health sciences, and ... diverse needs and interests of our students," said ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Touro University California Garners Grant From Long Foundation 2
... June 21 In a head-to-head, Phase III ... System versus tobramycin inhalation solution in cystic fibrosis patients ... non-inferiority for mean percent change in forced expiratory volume ... of treatment was achieved.  Patients receiving Cayston had a ...
... 21, 2010 The Pharmaceuticals practice at,MarketsandMarkets is pleased to announce a new ... , , ... Confectionery Market (2010,-2015) Market Report. Early buyers will receive 10% customization of reports, http://www.marketsandmarkets.com/Market-Reports/diet-food-247.html ... The global diet ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 2PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 3PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 4World Diet Food and Confectionery Market (2010 -2015): MarketsandMarkets 2World Diet Food and Confectionery Market (2010 -2015): MarketsandMarkets 3World Diet Food and Confectionery Market (2010 -2015): MarketsandMarkets 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 According to ... Business Journal , Endo International, one of several manufacturing ... thousands of transvaginal claims for $830 million (in re: ... Litigation (MDL No. 2325). Melinda Helbock, Founder of The ... agrees with the settlement and is pleased to see ...
(Date:7/31/2014)... today in Genes & Development , Dr ... DNA Replication group, in collaboration with Brookhaven National ... involved in the enzyme that governs DNA duplication ... using synthetic, chemical and structural biology approaches, the ... duplicating genetic information embraces DNA through a gated ...
(Date:7/31/2014)... July 31, 2014 Rich Dad® Education ... yard sale to benefit Habitat for Humanity. The yard sale ... raised with 100% of the proceeds donated to Habitat for ... not sold at the event were donated to the Habitat ... North Fort Myers, Florida 33903. , Of the over ...
(Date:7/31/2014)... Transplant surgeons often feel emotionally drained and overextended, ... study suggests. Nearly half of the transplant ... sense of personal accomplishment and four out of ... "Burnout is common in medicine, especially in ... Abouljoud, director of the Henry Ford Transplant Institute, ...
(Date:7/31/2014)... BUFFALO, N.Y. Athletes and others reporting cognitive difficulties ... had a concussion. But is it really a concussion? ... faculty finds that many of the same symptoms are ... and/or balance system, known collectively as cervical/vestibular injuries. , ... 128 patients some of whom were professional athletes ...
Breaking Medicine News(10 mins):Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2Health News:Molecular gate that could keep cancer cells locked up 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Is it really a concussion? Symptoms overlap with neck injuries so diagnosis is tough call 2Health News:Is it really a concussion? Symptoms overlap with neck injuries so diagnosis is tough call 3
... Ga., Sept. 19 Dominium Benefits, LLC,continues its ... its team. "We are very excited to include ... further our ability to provide,successful results for our ... Benefits, LLC, the next generation employee benefits brokerage,and ...
... four people in westernized countries experience pain or discomfort ... to offer except anti-acid medicines, which usually dont work. ... found evidence that an abnormal amount of inflammatory cells ... a fresh way of understanding the common complaint. , ...
... 19 Billian,s HealthDATA, the industry,s,only end-to-end resource ... they have recently completed the updates to their ... addition to the updated,information about the facilities and ... increase in the number of overall contacts compared ...
... Sept. 19 Former Speaker of the,House and founder ... a group of conservative Republican lawmakers on Capitol Hill,today ... in the,Congress over the State Children,s Health Insurance Program ... he was insistent that Congress,not lose sight of the ...
... BOSTON, Sept. 19 The United States District,Court ... approval of,two Proposed Settlements on behalf of a ... drugs. Plaintiffs filed the lawsuits, New,England Carpenters Health ... D.C. 37 Health & Security Plan v. Medi-Span, ...
... First and Only Nasal Spray Influenza Vaccine for Young Children in ... Available for 2007-2008 ... that the U.S. Food and Drug Administration (FDA) has approved the,expanded ... five years of age. FluMist is now approved for active,immunization for ...
Cached Medicine News:Health News:Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction 2Health News:Billian's HealthDATA Completes Comprehensive Long Term Care Database Update 2Health News:Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a 'Clean' SCHIP Six-Month Extension 2Health News:Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals 2Health News:Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals 3Health News:FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age 2Health News:FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age 3Health News:FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age 4Health News:FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age 5
... Independent controls for Digital ... stainless steel front. Anodized aluminum ends. ... stainless steel floor. , Oversized refrigeration ... 10C , Positive seal self-closing doors. ...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
Medicine Products: